Holen Sie sich die Stockscreener-App
23.45
6.20%
1.295
Schlusskurs vom Vortag:
$22.16
Offen:
$24
24-Stunden-Volumen:
111.71M
Relative Volume:
4.32
Marktkapitalisierung:
$5.36B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
33.99
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
+48.77%
1M Leistung:
+36.51%
6M Leistung:
-50.74%
1J Leistung:
-31.72%
1-Tages-Spanne:
$22.43
$26.03
1-Wochen-Bereich:
$15.21
$26.03
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
23.52 | 5.05B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.17 | 57.09B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
120.61 | 51.65B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.16 | 45.70B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.45 | 36.69B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
534.92 | 23.19B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Trending Tickers Today: Hims & Hers, BlackRock, Shell, and GSK Draw Investor Attention - Meyka
Hims & Hers Soars 41% as Peace Pact with Novo Nordisk Unlocks Branded Wegovy and Ozempic - FXLeaders
Hims & Hers Burns $546M In Short Bets After Novo Nordisk Deal Sends Stock Soaring To Best Day Ever - Stocktwits
Needham upgrades Hims & Hers (HIMS) to Buy on March 9, 2026 - Meyka
Weight-Loss Truce: Hims & Hers Wins Novo Nordisk Deal, Soars 40% - NAI500
A Look At Hims & Hers Health (HIMS) Valuation After Novo Nordisk GLP 1 Partnership And Legal Truce - Yahoo Finance
Hims & Hers, Roku, Oracle, Autozi And Joby Aviation: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Stock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug Deal - AOL.com
Novo, Hims & Hers Make Up, Agree To Sell GLP-1s Together - Law360
HIMS Surges as Citi Upgrades on Novo Nordisk Deal - GuruFocus
Hims & Hers: Not Selling Yet (NYSE:HIMS) - Seeking Alpha
Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s - The Hill
HIMS Surges Over 40% After Partnership with Novo Nordisk - GuruFocus
Hims & Hers Health boosted at Citi on Novo Nordisk partnership - Seeking Alpha
AI for investors - MLQ.ai
Hims & Hers Health: The Juice Is Worth The Squeeze (NYSE:HIMS) - Seeking Alpha
Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform - Yahoo Finance
Hims & Hers Short Squeeze Is Looking Dangerous (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
Uber expands Women Preferences, Hims & Hers stock skyrockets - Yahoo Finance
Novo Nordisk Hims And Hers Deal Reframes Obesity Drug Growth Story - Yahoo Finance
Novo Nordisk and Hims End Their Ozempic War. Here’s What It Means for You - Gizmodo
Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here? - Barchart.com
Hims & Hers rockets higher on potential Novo Nordisk deal - GuruFocus
Daily Digest: OpenAI robotics head heads for exit, S.F. telehealth Hims and Hers rockets 40% - The Business Journals
Hims & Hers Announces Strategic Shift for US Weight Loss Business - Happi | Household And Personal Products Industry
Hims & Hers Made a Surprising Concession to End Its GLP‑1 Beef With Novo Nordisk - inc.com
Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge - Benzinga
Hims and Novo End Feud With Obesity Drug Deal - GuruFocus
Hims & Hers Jumps 47% as Novo Nordisk Weighs New Weight-Loss Dru - GuruFocus
Hims & Hers, Novo Nordisk Reunite in GLP-1 Deal Weeks After Lawsuit - Athletech News
Hims & Hers: Repartnering With Novo Removes Legal Overhang and Reshapes Weight Loss Segment - Morningstar
Needham Upgrades Hims & Hers Stock (HIMS) after Novo Nordisk Deal Resets Weight Loss Outlook - TipRanks
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration - MSN
Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (13 Ratings) - Benzinga
Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers - WSJ
HIMS Stock Surges Over 37% Amid Market Rally - GuruFocus
Hims & Hers Stock Soars. Its Weight-Loss Drug Battle With Novo Nordisk Takes a Surprising Twist. - Barron's
Hims & Hers stock: why today's gains are unlikely to be sustainable - Invezz
Hims & Hers Health Inc (HIMS) Shares Up 40.72% on Mar 9 - GuruFocus
Hims & Hers Shares Surge on Novo Nordisk Deal Report - TradingView
Why Hims & Hers Health (HIMS) Stock Is Up Today - Yahoo Finance
Hims & Hers abandons plan for cheaper Wegovy knockoff after FDA warningLos Angeles Times - Los Angeles Times
Hims & Hers shares jump after weight-loss drug deal with Novo Nordisk - Financial Times
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc.HIMS - Business Wire
HIMS Stock Surges Over 38% to New Heights - GuruFocus
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? - The Motley Fool
Hims & Hers & Novo Nordisk Partner for Ozempic, Wegovy Sales | 2026News and Statistics - IndexBox
HIMS Upgraded to Buy by Needham with $30 Target Price | HIMS Sto - GuruFocus
Hims & Hers Stock Jumps on Reports Novo Nordisk Obesity Deal - GuruFocus
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy - Stocktwits
Novo Nordisk & Hims & Hers Deal: Wegovy, Ozempic Sales on PlatformNews and Statistics - IndexBox
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.94%
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):